Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD ISIN · CA2518341078 TSXV Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2023-06-28 Regulatory Filings
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (F).pdf
Regulatory Filings Classification · 95% confidence The document is an attestation by the CEO regarding the interim financial report and management report for the period ended April 30, 2023. It explicitly states it is an attestation for an emerging issuer under Canadian regulation 52-109, confirming the accuracy and fair presentation of the interim financial documents. The text does not contain the actual financial statements or substantive financial data but is a certification letter about those reports. According to the Certification Rule, such attestations should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR). The document length is 3637 characters, which is relatively short and consistent with a certification letter rather than a full report.
2023-06-28 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification form titled 'Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate' signed by the Interim CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended April 30, 2023. The content is primarily an officer certification regarding the interim filings, not the filings themselves. It explicitly states it is a certification under National Instrument 52-109 for venture issuers and does not include the actual financial data or analysis. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (3099 characters), consistent with a certification letter rather than a full report.
2023-06-28 English
52-109FV2 - Certification of interim filings - CFO (F).pdf
Regulatory Filings Classification · 95% confidence The document is an attestation by the interim CFO of Groupe Santé Devonian Inc. regarding the review of the interim financial report and interim management report for the period ended April 30, 2023. It explicitly states it is an attestation for an emerging issuer under Canadian regulation 52-109, confirming the accuracy and fair presentation of the interim documents. The document does not contain actual financial statements or substantive financial data but is a certification letter about the interim reports. According to the Certification Rule, such attestations should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR). The document length is 3651 characters, which is relatively short and consistent with a certification letter rather than a full report.
2023-06-28 English
Interim MD&A - French.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'RAPPORT DE GESTION' for the quarter ended April 30, 2023, and it provides a detailed management report including financial performance overview, research and development updates, and business activities for the quarter. It references interim financial statements and discusses operational and strategic matters in detail. The length is substantial (15,000 characters), and it contains substantive financial and operational data rather than just an announcement or certification. The document is a quarterly management report, which corresponds to an Interim / Quarterly Report (IR) filing type. Q3 2023
2023-06-28 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q3-2023 MANAGEMENT REPORT FOR THE QUARTER ENDED APRIL 30, 2023' and provides a detailed overview of the company's activities, financial situation, research and development progress, and business strategy for the quarter. It includes substantive financial data and analysis, references to interim financial statements, and forward-looking statements typical of a management discussion and analysis report. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-06-28 English
Interim financial statements/report – French.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled "États financiers intermédiaires résumés consolidés" which translates to "Condensed Consolidated Interim Financial Statements" for the nine-month period ended April 30, 2023. It contains detailed financial statements including balance sheets, income statements, statements of changes in equity, and cash flow statements, all marked as unaudited. The notes mention compliance with IFRS IAS 34, which governs interim financial reporting. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure clearly identify it as an interim or quarterly financial report containing substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2023
2023-06-28 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.